Emcure, the parent company of Gennova Biopharmaceuticals that's developing messenger RNA (mRNA) COVID-19 vaccine, said it is working on backward integration of its jab to reduce dependence on key imported raw materials, reagents and enzymes that go into the manufacturing.

"A lot of these key starting materials that go into the mRNA vaccine – Modernas and Pfizers of the world – rely on a lot of European and US suppliers. We saw that as a potential bottleneck," Vikas Thapar, President, Corporate Development & Strategy at Emcure, told Moneycontrol.

Leave a Reply

Your email address will not be published. Required fields are marked *